Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06632938
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-10-08
Brief Title:
A Study to Evaluate Adverse Events and How the Drug Moves Through the Body From Subcutaneous SC and Intravenous IV Doses of ABBV-382 in Healthy Adult Chinese Volunteers
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Randomized Single-blind Placebo-controlled Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Single Doses of ABBV-382 in Healthy Adult Chinese Volunteers
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main objectives of this study are to evaluate the safety tolerability pharmacokinetics and immunogenicity of single subcutaneous SC and intravenous IV doses of ABBV-382 in healthy adult Chinese volunteers
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None